TSOI Stock Overview
Therapeutic Solutions International, Inc.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Therapeutic Solutions International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0058 |
| 52 Week High | US$0.037 |
| 52 Week Low | US$0.0046 |
| Beta | 1.59 |
| 1 Month Change | -8.66% |
| 3 Month Change | -43.69% |
| 1 Year Change | -73.05% |
| 3 Year Change | 163.64% |
| 5 Year Change | -6.45% |
| Change since IPO | -96.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TSOI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.9% | -0.4% | 2.3% |
| 1Y | -73.0% | 7.9% | -9.4% |
Return vs Industry: TSOI underperformed the US Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: TSOI underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| TSOI volatility | |
|---|---|
| TSOI Average Weekly Movement | 19.4% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TSOI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: TSOI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Tim Dixon | https://www.therapeuticsolutionsint.com |
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products include QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production.
Therapeutic Solutions International, Inc. Fundamentals Summary
| TSOI fundamental statistics | |
|---|---|
| Market Cap | US$15.41m |
| Earnings (TTM) | -US$4.06m |
| Revenue (TTM) | US$242.35k |
63.6x
P/S Ratio-3.8x
P/E RatioIs TSOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSOI income statement (TTM) | |
|---|---|
| Revenue | US$242.35k |
| Cost of Revenue | US$48.38k |
| Gross Profit | US$193.97k |
| Other Expenses | US$4.25m |
| Earnings | -US$4.06m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0015 |
| Gross Margin | 80.04% |
| Net Profit Margin | -1,675.53% |
| Debt/Equity Ratio | 60.4% |
How did TSOI perform over the long term?
See historical performance and comparison